Chipiron
Chipiron is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Chipiron.
Chipiron is a company.
Key people at Chipiron.
Chipiron is a French deeptech startup founded in 2020 that designs and manufactures compact, ultra-low-field MRI machines to make magnetic resonance imaging accessible in standard clinics, local care centers, private practices, and mobile units.[1][2][4] The company serves the healthcare industry, primarily targeting cancer detection and other diagnostics by addressing the high cost, size, and infrastructure demands of traditional high-field MRI systems with lightweight, inexpensive, open full-body scanners.[1][2][4] Chipiron has raised $20.8M total, including a $17M Series A in 2025 led by Blast (with EIC Fund, iXcore, France2030, EIC Accelerator, and Bpifrance), following pre-seed and seed rounds, and is advancing toward prototypes and 2026 clinical trials.[1][4]
Its core product leverages patented quantum SQUID detection, AI noise cancellation, ultra-light cooling at 4K, and low-field AI reconstruction to achieve high signal-to-noise ratios (up to 10x improvement) in open environments without heavy magnets or shielding.[2]
Chipiron emerged in 2020 from the Entrepreneur First accelerator program in Paris, France, with the ambitious goal of revolutionizing MRI by creating machines with low magnetic fields.[1][3] CEO and cofounder Evan Kervella leads the team, though specific backgrounds for other founders are not detailed in available sources.[4] Early traction included $1.1M pre-seed in 2021, non-dilutive grants totaling $1.1M from 2022-2023 for R&D, and a $2.7M seed in 2023 led by Exor Ventures and Unruly Capital.[4] A pivotal moment came in May 2025 with the $17M Series A, enabling prototype finalization and hospital deployment prep.[1][4]
Headquartered at 2/8 Rue Gaston Rebuffat in Paris, the company has filed one patent (application December 2021) for a low-noise RF detection system using SQUIDs, underscoring its quantum-tech foundation.[1]
Chipiron's innovations center on overcoming traditional MRI barriers like size, cost, and site requirements:
These enable "mini-IRM" prototypes cheaper and more deployable than conventional systems.[1]
Chipiron rides the convergence of quantum sensing, AI imaging, and decentralized healthcare trends, democratizing MRI amid global shortages—exacerbated by high costs (traditional machines exceed $1M+) and installation needs.[1][2][4] Timing aligns with post-pandemic demand for point-of-care diagnostics, cancer early-detection pushes, and Europe's deeptech funding via EIC/France2030.[4] Market tailwinds include aging populations driving imaging needs and AI/quantum advances lowering barriers; Chipiron influences by pioneering clinically viable low-field MRI, potentially expanding access in underserved areas and accelerating AI-quantitative analysis for diseases like cancer.[2][4]
As an Entrepreneur First alum, it exemplifies Europe's hardware innovation ecosystem alongside peers in quantum gravimetry and lab automation.[3]
Chipiron is poised to prototype its mini-MRI in 2025 and launch clinical trials in 2026, scaling toward commercialization if trials validate performance.[1][4] Key shapers include quantum sensor maturation, AI reconstruction improvements, and regulatory nods for low-field tech; success could evolve its role from pioneer to standard-setter, transforming global MRI from centralized hospitals to ubiquitous clinics.[2][4] Risks involve trial outcomes and competition from high-field incumbents, but its $20.8M war chest and tech edge position it to fundamentally alter medical imaging accessibility—fulfilling its day-one mission to end cancer through scalable MRI.[1][2][4]
Key people at Chipiron.
